Is Vitamin E Good for Fatty Liver? Who It May Help

TL;DR

• In one large trial (PIVENS), 800 IU of vitamin E a day for 96 weeks improved MASH in adults without diabetes (43% vs 19% on placebo), but did not improve scarring.
• The AASLD says vitamin E “can be considered in select individuals.” The European guideline says it cannot be recommended as a MASH treatment, citing the lack of large phase III trials and potential long-term risks.
• It is a doctor-directed option for MASH, not a supplement for everyone with fatty liver. Do not start high-dose vitamin E on your own.

Is Vitamin E Good for Fatty Liver?

It can help a small group of people, and the two major guidelines disagree on whether to use it. For most people with simple fatty liver (MASLD, formerly NAFLD), vitamin E is not part of the plan. For people with its inflamed form, MASH, who do not have diabetes, it is one option a hepatologist may discuss.

The reason it is on the table at all is one trial, PIVENS, published in the New England Journal of Medicine in 2010. Nothing since has replaced it with a larger study, which is why the guidelines are cautious.

What Did the PIVENS Trial Show?

PIVENS randomly assigned 247 adults with NASH and no diabetes to one of three groups for 96 weeks: vitamin E 800 IU daily (84 people), pioglitazone 30 mg daily (80), or placebo (83).

Outcome	Vitamin E	Placebo
Improvement in NASH on biopsy (the main goal)	43%	19%
ALT and AST (liver enzymes)	Reduced vs placebo	Less reduction
Fat in the liver and lobular inflammation	Reduced vs placebo	Less reduction
Fibrosis (scarring) score	No significant improvement	No change

Source: Sanyal et al., NEJM 2010. Pioglitazone’s main-goal result (34% vs 19%) did not reach the trial’s threshold for significance.

So vitamin E improved the picture of fat, inflammation and enzymes, but not scarring. The AASLD adds that a drop in ALT to 40 U/L or below, and by at least 30% from baseline, after starting vitamin E is associated with better biopsy findings. For more on those numbers, see ALT and AST levels in fatty liver.

What Do the AASLD and EASL Say?

	AASLD 2023	EASL–EASD–EASO 2024
Position	”Vitamin E can be considered in select individuals as it improves NASH in some patients without diabetes"	"Vitamin E cannot be recommended as a MASH-targeted therapy”
Why	Improved histology in PIVENS and a meta-analysis of trials	No large phase III trial showing histological benefit on MASH and fibrosis, plus potential long-term risks
Scarring	No antifibrotic benefit shown; not carefully studied in cirrhosis	No clear data on fibrosis improvement

The two statements are not as far apart as they sound. Both rest on the same trial, and both say the evidence on scarring is missing. The AASLD leaves room for individual decisions with the doctor. The European guideline grades its recommendation as weak, but still lands on “not recommended.”

The AASLD also mentions a retrospective study of 236 people with NASH and advanced fibrosis in which vitamin E users had lower rates of hepatic decompensation (37% vs 62%) and higher transplant-free survival (78% vs 49%). A study that looks back at records cannot prove the vitamin was the reason, which is why it is not the basis of any recommendation.

Who Is Vitamin E For?

Based on the guidance, a person would typically need all of these:

• MASH, not just fat. The trial enrolled people with biopsy-proven NASH. Fatty liver on ultrasound alone is a different situation.
• No diabetes. The AASLD’s wording and the PIVENS trial are about adults without diabetes.
• A doctor in charge. The AASLD says the risks should be discussed before starting long-term, high-dose (such as 800 IU daily) therapy.

If you have type 2 diabetes, other options, including diabetes medicines, are usually the starting point; ask your hepatologist. If you have cirrhosis, vitamin E has not been carefully studied. Do not add it on your own.

Is High-Dose Vitamin E Safe?

This is where caution comes from.

• Bleeding and stroke. The AASLD says concern about bleeding, and specifically hemorrhagic stroke, has been raised, but prospective data are needed to confirm it. The NIH Office of Dietary Supplements also warns that vitamin E can increase bleeding risk in people taking blood thinners such as warfarin.
• Prostate cancer. The AASLD says data on a relationship with prostate cancer are conflicting.
• Dose ceiling. The NIH sets the adult upper limit for supplemental vitamin E at 1,000 mg a day (1,500 IU of natural vitamin E, 1,100 IU of the synthetic form). The trial dose of 800 IU natural vitamin E is about 540 mg, which is about half that ceiling and roughly 35 times the 15 mg adult recommended daily amount.
• Form matters. The AASLD lists the dose as natural (RRR-alpha) vitamin E 800 IU daily. Over-the-counter bottles vary, and IU values are not the same for natural and synthetic forms.

Tell your doctor about every supplement and medicine you take, especially blood thinners and aspirin.

Can You Get Vitamin E From Food Instead?

Yes for ordinary needs, no for the trial dose. Nuts, seeds and vegetable oils are the main dietary sources, and they are staples of the Mediterranean-style pattern that helps fatty liver anyway (see the fatty liver diet and is olive oil good for fatty liver). Eating them keeps you out of deficiency. It will not replicate what was tested in PIVENS, and it is not a treatment for MASH.

What Matters More Than Vitamin E?

Weight loss. The AASLD says 3% to 5% loss improves liver fat, while more than 10% is generally required to improve inflammation and scarring. That is a bigger lever for most people than any supplement (see how to reverse fatty liver). If your tests suggest significant scarring, approved medicines such as resmetirom are worth asking about. Supplements in general are covered in the fatty liver diet page, and the milk thistle evidence is in is milk thistle good for fatty liver.

The Bottom Line

Vitamin E is not a general fatty liver supplement. One strong trial shows 800 IU a day can improve MASH in adults without diabetes, but not scarring, and long-term safety at that dose is unsettled. The AASLD allows it in select individuals; EASL does not recommend it. If you think you might be a candidate, take the question to your hepatologist rather than the supplement aisle.

Sources

• Sanyal AJ et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis (New England Journal of Medicine, 2010)
• AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (Hepatology, 2023)
• EASL–EASD–EASO Clinical Practice Guidelines on the management of MASLD (Journal of Hepatology, 2024)
• NIH Office of Dietary Supplements: Vitamin E fact sheet

This article is for informational purposes only and is not medical advice. Talk to your doctor or hepatologist about your specific situation.